好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Online CME is Successful in Supporting the Clinical Integration of Behaviors Associated with the Diagnosis and Optimal Management of Migraine Among Neurologists, Primary Care Physicians, and other Specialists
Headache
P9 - Poster Session 9 (5:00 PM-6:00 PM)
15-001
This study assessed the ability of an online CME program to improve the clinical actions of physicians in the greatest position to impact migraine diagnosis and management. 
Migraine is a common chronic neurologic disease which remains underrecognized, underdiagnosed and undertreated. People who are members of underrepresented populations are at particular risk for receiving suboptimal care. 

The CME activity was a 45-minute video recorded and chapterized program on 5 topics, including: symptom burden, diagnosis, acute medication, preventive medication, and equitable care among in underrepresented populations. The impact of the education was measured with an intent to change survey, a validated surrogate measure for actual changes in clinical practice. 30-60 days after participation in the activity, learners were asked to complete a survey about the type of changes they made in practice based on the education and to identify any barriers to implementation. Data were collected from 2/29/2024 through 9/17/2024.

A total of 74 physicians in the target audience (12 neurologists, 51 PCPs, 1 obstetrician, and 10 other specialists) responded to the survey. Between 69%-87% reported that they have modified or are now integrating the following actions: routinely asking about migraine symptom burden and the number of migraine- and headache-free days per month; consider route of administration when recommending acute medication; counseling patients that 2 hour pain freedom is goal of acute medication treatment, discussing the goals of preventive therapies with patients, and identifying social determinants of health in all patients with migraine. Although 70%-80% of respondents reported having no barriers to implementing any of the changes, lack of time was the most frequently cited (14% selected this) barrier.  

This study provides evidence that online CME encourages multiple physician groups to make practice changes supporting timely diagnosis and appropriate management. Future education should prioritize time-sensitive strategies for diagnosing and managing migraine.

Authors/Disclosures
Thomas Finnegan, Jr., PhD (Medscape 好色先生)
PRESENTER
Dr. Finnegan has nothing to disclose.
Kathy Merlo Ms. Merlo has nothing to disclose.
Catherine Capparelli, CHCP Ms. Capparelli has nothing to disclose.
Rashmi B. Halker Singh, MD, FAAN (Mayo Clinic) Dr. Halker Singh has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Halker Singh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie. Dr. Halker Singh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Halker Singh has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Neurology & Neuroscience Reports. Dr. Halker Singh has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache Journal. Dr. Halker Singh has received publishing royalties from a publication relating to health care. Dr. Halker Singh has received personal compensation in the range of $5,000-$9,999 for serving as a CME speaker with Pri-med. Dr. Halker Singh has received personal compensation in the range of $500-$4,999 for serving as a CME speaker with Medscape.
Dawn C. Buse, PhD (Dawn C. Buse, PhD) Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranicsa. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.